Replimune has reached an important milestone in oncology with the FDA’s accelerated approval of tudriqev (vusolimogene oderparepvec-wtpg), previously identified as RP1, in combination with Bristol Myers Squibb’s OPDIVO (nivolumab). Granted on August 6, 2026, the approval applies to adults with unresectable, advanced cutaneous melanoma that has progressed after treatment with an...
